Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANAC NASDAQ:CLDX NASDAQ:DVAX NASDAQ:MNKD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANACArctos NorthStar Acquisition$10.19$9.75$9.44▼$10.20$402.81MN/A53,611 shs705 shsCLDXCelldex Therapeutics$22.19+1.0%$21.36$14.40▼$47.00$1.47B1.22852,743 shs768,053 shsDVAXDynavax Technologies$10.86-1.1%$10.38$9.22▼$14.63$1.30B1.091.35 million shs1.28 million shsMNKDMannKind$3.75-0.8%$3.91$3.51▼$7.63$1.14B1.022.55 million shs2.54 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANACArctos NorthStar Acquisition0.00%0.00%0.00%0.00%0.00%CLDXCelldex Therapeutics0.00%-4.97%+0.98%+9.36%-36.20%DVAXDynavax Technologies0.00%-4.40%+5.64%-3.55%+3.13%MNKDMannKind0.00%-7.64%+4.02%-24.40%-29.78%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANACArctos NorthStar AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACLDXCelldex Therapeutics1.2607 of 5 stars3.41.00.00.02.10.00.0DVAXDynavax Technologies4.2698 of 5 stars3.31.00.04.73.31.71.9MNKDMannKind3.4052 of 5 stars3.63.00.00.02.51.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANACArctos NorthStar Acquisition 0.00N/AN/AN/ACLDXCelldex Therapeutics 2.89Moderate Buy$50.11125.83% UpsideDVAXDynavax Technologies 2.50Moderate Buy$24.00120.99% UpsideMNKDMannKind 3.25Buy$9.86162.86% UpsideCurrent Analyst Ratings BreakdownLatest ANAC, CLDX, DVAX, and MNKD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/23/2025MNKDMannKindRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$10.00 ➝ $8.007/16/2025MNKDMannKindHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$9.006/13/2025CLDXCelldex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.005/9/2025CLDXCelldex TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$44.00 ➝ $38.005/9/2025CLDXCelldex TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$36.00 ➝ $31.005/9/2025CLDXCelldex TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$46.00 ➝ $43.005/7/2025DVAXDynavax TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$33.00 ➝ $31.005/6/2025CLDXCelldex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00(Data available from 8/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANACArctos NorthStar AcquisitionN/AN/A$0.18 per share56.23($0.63) per shareN/ACLDXCelldex Therapeutics$7.02M209.83N/AN/A$11.26 per share1.97DVAXDynavax Technologies$277.25M4.70$0.16 per share68.58$4.54 per share2.39MNKDMannKind$285.50M3.99$0.14 per share27.02($0.29) per share-12.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANACArctos NorthStar Acquisition$7.16MN/A0.00∞N/AN/A-70.78%3.97%N/ACLDXCelldex Therapeutics-$157.86M-$2.70N/AN/AN/A-2,366.07%-23.46%-22.35%8/6/2025 (Estimated)DVAXDynavax Technologies$27.31M-$0.52N/A22.16N/A-20.39%3.59%2.20%8/7/2025 (Estimated)MNKDMannKind$27.59M$0.1037.5016.30N/A10.12%-32.41%10.85%8/6/2025 (Estimated)Latest ANAC, CLDX, DVAX, and MNKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CLDXCelldex Therapeutics-$0.86N/AN/AN/A$1.13 millionN/A8/7/2025Q2 2025DVAXDynavax Technologies$0.12N/AN/AN/A$87.55 millionN/A8/6/2025Q2 2025MNKDMannKind$0.04N/AN/AN/A$77.82 millionN/A5/8/2025Q1 2025CLDXCelldex Therapeutics-$0.75-$0.81-$0.06-$0.81$1.08 million$0.70 million5/8/2025Q1 2025MNKDMannKind$0.03$0.04+$0.01$0.04$75.86 million$78.35 million5/6/2025Q1 2025DVAXDynavax Technologies$0.03-$0.11-$0.14-$0.77$70.01 million$68.16 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANACArctos NorthStar AcquisitionN/AN/AN/AN/AN/ACLDXCelldex TherapeuticsN/AN/AN/AN/AN/ADVAXDynavax TechnologiesN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANACArctos NorthStar AcquisitionN/A0.150.15CLDXCelldex TherapeuticsN/A21.6721.67DVAXDynavax Technologies0.4911.9310.84MNKDMannKindN/A2.362.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANACArctos NorthStar Acquisition71.06%CLDXCelldex TherapeuticsN/ADVAXDynavax Technologies96.96%MNKDMannKind49.55%Insider OwnershipCompanyInsider OwnershipANACArctos NorthStar AcquisitionN/ACLDXCelldex Therapeutics4.40%DVAXDynavax Technologies2.98%MNKDMannKind3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANACArctos NorthStar AcquisitionN/A39.53 millionN/ANot OptionableCLDXCelldex Therapeutics15066.38 million63.46 millionOptionableDVAXDynavax Technologies350120.08 million116.50 millionOptionableMNKDMannKind400303.93 million294.82 millionOptionableANAC, CLDX, DVAX, and MNKD HeadlinesRecent News About These CompaniesMannKind (NASDAQ:MNKD) Lowered to Hold Rating by Wall Street ZenAugust 3 at 3:51 AM | marketbeat.comFederated Hermes Inc. Cuts Stock Position in MannKind Corporation (NASDAQ:MNKD)August 3 at 3:01 AM | marketbeat.comH.C. Wainwright Affirms MannKind Corp (MNKD)’s ‘Buy’ Rating Buoyed by Product PipelineAugust 1 at 7:42 AM | insidermonkey.comWedbush Remains Bullish on MannKind Corporation (MNKD)August 1 at 5:18 AM | msn.comMannKind (MNKD) Expected to Announce Quarterly Earnings on WednesdayJuly 31, 2025 | marketbeat.comMannKind Corporation to Release Second Quarter 2025 Financial Results and Host Webcast on August 6, 2025July 30, 2025 | quiverquant.comQMannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025July 30, 2025 | globenewswire.comAnalysts Estimate MannKind (MNKD) to Report a Decline in Earnings: What to Look Out forJuly 30, 2025 | zacks.comVictory Capital Management Inc. Acquires 137,833 Shares of MannKind Corporation (NASDAQ:MNKD)July 30, 2025 | marketbeat.comRBC Capital Lowered the PT on MannKind Corporation (MNKD), Kept a Buy RatingJuly 28, 2025 | insidermonkey.comMannKind Corporation (MNKD) Presented Inhaled Insulin Therapy At American Diabetes AssociationJuly 23, 2025 | insidermonkey.comMannKind (NASDAQ:MNKD) Given New $8.00 Price Target at Royal Bank Of CanadaJuly 23, 2025 | marketbeat.comHC Wainwright Estimates MannKind FY2025 EarningsJuly 21, 2025 | marketbeat.comMannKind Corporation (NASDAQ:MNKD) Receives Average Rating of "Buy" from AnalystsJuly 19, 2025 | marketbeat.comMannKind (NASDAQ:MNKD) Upgraded at Wall Street ZenJuly 19, 2025 | marketbeat.comMannKind Corporation (NASDAQ:MNKD) Director Steven B. Binder Sells 75,367 SharesJuly 18, 2025 | marketbeat.comInsider Selling: MannKind Corporation (NASDAQ:MNKD) Director Sells 75,367 Shares of StockJuly 18, 2025 | insidertrades.comHC Wainwright Estimates MannKind's Q2 Earnings (NASDAQ:MNKD)July 18, 2025 | marketbeat.comMannKind's (MNKD) Buy Rating Reiterated at HC WainwrightJuly 16, 2025 | marketbeat.comWells Fargo Maintains a Buy Rating on MannKind Corporation (MNKD), Sets a $9 PTJuly 11, 2025 | insidermonkey.comMannKind (NASDAQ:MNKD) Hits New 52-Week Low - Here's WhyJuly 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANAC, CLDX, DVAX, and MNKD Company DescriptionsArctos NorthStar Acquisition NASDAQ:ANACArctos NorthStar Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It focuses on sports, media, and entertainment sectors. The company was founded in 2020 and is based in Dallas, Texas.Celldex Therapeutics NASDAQ:CLDX$22.19 +0.21 (+0.96%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$22.52 +0.33 (+1.49%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Dynavax Technologies NASDAQ:DVAX$10.86 -0.12 (-1.09%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$10.88 +0.02 (+0.14%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.MannKind NASDAQ:MNKD$3.75 -0.03 (-0.79%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.78 +0.03 (+0.69%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
